News

The acquisition of Hyperion occurred through a merger under Section 251(h) of the General Corporation Law of the State of Delaware following Horizon’s successful tender for 86% of

The studies, led by Moffitt researchers Heather Jim, PhD, Diane Portman, MD, Howard McLeod, PharmD, and Gillian Bell, PharmD will examine a number of genetic variants as predictors

Gen Ilac was granted the exclusive right to sell Iclusig as an investigational product in Turkey on a named-patient basis and will provide associated medical affairs and regulatory

Data also showed that there was a statistically significant survival benefit of 52% relative risk reduction of death or graft loss at 5 years post-transplant (hazard ratio=0.477, p=0.0045).

The trial has been named the "CLEAN-CF" trial which refers to "Clearing Lungs with ENaC inhibition in Cystic Fibrosis". The CLEAN-CF study will include CF patients regardless of

Stakeholders throughout the drug development enterprise have caught the patient centricity bug and it is highly contagious. Sponsors, CROs, investigative sites, technology solution and service vendors, and ethical

Virirec, Apricus’ novel topical on-demand treatment for erectile dysfunction ("ED") is also marketed in other European countries as Vitaros and in Belgium as Vytaros. This is the fifth

The start of field-based commercialization efforts for Xalkori is part of the company’s aim to bring treatment options for challenging cancers to patients. In the US, Xalkori is

EpiTherapeutics has developed a library of first-in-class, selective small molecule inhibitors of epigenetic regulation of gene transcription, in particular histone demethylases. Gilead Research and Development executive vice-president and